[Form 4] Revolution Medicines, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Revolution Medicines insider sale to cover tax withholding following RSU vesting. Chief Financial Officer Jack Anders reported a sale of 2,320 shares of Revolution Medicines common stock on 09/16/2025 at an average price of $45.8249 per share, executed under a pre-existing Rule 10b5-1 instruction adopted May 31, 2023 to satisfy tax withholding obligations tied to RSU vesting after July 15, 2023. After the transaction Mr. Anders beneficially owned 110,994 shares, which the filing notes includes 48,275 restricted stock units. The Form 4 is signed and dated 09/18/2025.

Positive

• Transaction executed under a Rule 10b5-1 instruction, indicating a pre-planned disposition rather than discretionary trading
• Clear disclosure of tax-withholding purpose for the sale tied to RSU vesting
• Form 4 filed and signed, demonstrating compliance with reporting obligations

Negative

• Insider ownership decreased by the 2,320-share sale (reported), reducing direct holdings
• Filing lacks context on total outstanding shares or percentage ownership, limiting assessment of materiality

Insights

Financial Analyst

TL;DR: Routine insider sale under a 10b5-1 plan to meet tax withholding on vested RSUs; ownership remains substantial.

The sale of 2,320 shares at $45.8249 appears to be a mechanistic tax-withholding disposition rather than an opportunistic open-market trade. The use of a Rule 10b5-1 instruction adopted in 2023 provides pre-planned execution, which reduces concerns about trading on material nonpublic information. The filing discloses total beneficial ownership of 110,994 shares including 48,275 RSUs, which is a meaningful portion of reported holdings but the Form 4 does not provide company-wide share counts or percentage ownership, limiting assessment of materiality to shareholders broadly.

Corporate Governance Expert

TL;DR: Governance practices appear followed: sale executed under documented 10b5-1 plan and properly reported on Form 4.

The reporting indicates compliance with Section 16 reporting and reliance on a documented Rule 10b5-1 instruction letter to satisfy tax withholding for RSU vesting. The timely filing (signed 09/18/2025) and inclusion of an explanation of the transaction align with transparent insider reporting standards. The disclosure shows retained holdings including restricted units, but the Form 4 does not disclose any amendments or other related arrangements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Anders Jack

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		S(1)		2,320	D	$45.8249	110,994(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 48,275 restricted stock units.

	/s/ Jack Anders	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jack Anders sell and why (RVMD)?

The CFO sold 2,320 shares of Revolution Medicines common stock on 09/16/2025 to satisfy tax withholding related to RSU vesting.

At what price were the RVMD shares sold?

The reported sale price was $45.8249 per share.

How many shares does the reporting person own after the transaction?

The Form 4 reports 110,994 shares beneficially owned following the transaction, which includes 48,275 restricted stock units.

Was the sale discretionary or pre-planned?

The sale was executed pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, indicating it was pre-planned.

When was the Form 4 signed and filed?

The Form 4 bears the reporting person’s signature dated 09/18/2025.